32 lbs in 3 months on GLP-1s: real result or red flag?

What did @dr.kimchee actually say?

The creator went out of their way to correct a public assumption: they are not on Ozempic. They said plainly, "I'm on Mounjaro, okay? I'm not on Ozempic." The correction came after apparent public criticism about body changes, with commenters assuming semaglutide use. The caption claims 32 pounds lost in three months, though that specific figure doesn't appear in the transcript itself. The creator also referenced stopping Ozempic previously because "family members can't get it," which gestures at the real-world shortage problem that affected semaglutide supply from 2022 into 2024. So the core message here is: this person is using tirzepatide (Mounjaro), not semaglutide (Ozempic), and they want people to know the difference.

Does the science back this up?

Tirzepatide and semaglutide are genuinely different drugs with different mechanisms, and the distinction matters clinically. Tirzepatide (Mounjaro/Zepbound) is a dual GIP and GLP-1 receptor agonist. Semaglutide (Ozempic/Wegovy) only hits GLP-1 receptors. That dual action appears to produce greater average weight loss in head-to-head comparisons.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at the highest dose (15 mg) produced roughly 22.5% body weight reduction over 72 weeks in adults without diabetes. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4 mg produced about 14.9% weight reduction over 68 weeks. These aren't equivalent outcomes, though comparing across trials is imperfect. A 32-pound loss in three months is aggressive but not impossible depending on starting weight, though it sits at the faster end of typical clinical responses.

What did they get wrong (or right)?

Honestly, the creator got the main distinction right. Mounjaro and Ozempic are not the same drug, not the same mechanism, and not the same expected outcome. Conflating them is a common public error, so correcting it is legitimate and useful.

What's murkier is the 32-pound-in-three-months claim from the caption. That's roughly 2.7 pounds per week, which exceeds average clinical trial rates. SURMOUNT-1 showed about 1-2 pounds per week in early weeks, tapering over time. It's not impossible, especially at higher starting weights, but presenting an outlier result without that context can set unrealistic expectations for viewers who might pursue the same medication. The creator didn't explain their starting weight, dose, or any lifestyle changes, all of which significantly affect outcomes. That omission isn't a lie, but it shapes perception in a way that could mislead.

What should you actually know?

Tirzepatide and semaglutide are both GLP-1 class medications used for weight management, but they work differently and produce different average results. Mounjaro is approved by the FDA for type 2 diabetes; Zepbound is the same drug approved for chronic weight management. Ozempic is approved for type 2 diabetes; Wegovy is semaglutide approved for weight management. Using the diabetes-branded version off-label for weight loss is common but worth understanding.

The shortage issue the creator referenced is real. The FDA tracked semaglutide shortages actively from 2022 through much of 2023, affecting patient access. Some people switched medications not by clinical choice but by availability, which is a real access and safety issue that gets glossed over in transformation content.

Weight loss results on these medications vary widely based on dose, adherence, diet, baseline metabolic health, and how long someone stays on the drug. Individual results posted on social media are not clinical data.

Bottom line on this video

The creator's core correction is accurate and worth amplifying. Mounjaro is not Ozempic. The 32-pound claim is unverifiable from this content and lacks the context needed to be meaningful. If you're considering either medication, the right starting point is a licensed provider who can review your full history, not a TikTok comment section.